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Abstract
Objectives To investigate the value of second-opinion evalu-
ation of multiparametric prostate magnetic resonance imaging
(MRI) by subspecialised uroradiologists at a tertiary centre for
the detection of significant cancer in transperineal fusion pros-
tate biopsy.
Methods Evaluation of prospectively acquired initial and
second-opinion radiology reports of 158 patients who
underwent MRI at regional hospitals prior to transperineal
MR/untrasound fusion biopsy at a tertiary referral centre over
a 3-year period. Gleason score (GS) 7-10 cancer, positive
predictive value (PPV) and negative (NPV) predictive value
(±95 % confidence intervals) were calculated and compared
by Fisher’s exact test.
Results Disagreement between initial and tertiary centre
second-opinion reports was observed in 54 % of cases (86/
158). MRIs had a higher NPV for GS 7-10 in tertiary centre
reads compared to initial reports (0.89 ± 0.08 vs 0.72 ± 0.16; p
= 0.04), and a higher PPV in the target area for all cancer (0.61
± 0.12 vs 0.28 ± 0.10; p = 0.01) and GS 7-10 cancer (0.43 ±
0.12 vs 0.2 3 ± 0.09; p = 0.02). For equivocal suspicion, the
PPV for GS 7-10 was 0.12 ± 0.11 for tertiary centre and 0.11
± 0.09 for initial reads; p = 1.00.
Conclusions Second readings of prostate MRI by
subspecialised uroradiologists at a tertiary centre significantly
improved both NPV and PPV. Reporter experience may help
to reduce overcalling and avoid overtargeting of lesions.
Key Points
• Multiparametric MRIs were more often called negative in
subspecialist reads (41 % vs 20 %).
• Second readings of prostate mpMRIs by subspecialist
uroradiologists significantly improved NPVand PPV.
• Reporter experience may reduce overcalling and avoid
overtargeting of lesions.
• Greater education and training of radiologists in prostate
MRI interpretation is advised.
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Introduction
Multiparametric magnetic resonance imaging (mpMRI) of the
prostate is increasingly used to identify men with significant
prostate cancer [1]. It has been shown to be effective for the
detection and local staging of prostate cancers and can prefer-
entially detect clinically relevant index tumours of higher
grade and a size >5 mm [2]. A normal mpMRI has been
shown to have a high negative predictive value (NPV) (90-
98 %) for the presence of clinically significant disease in bi-
opsy [3–5]. However, these literature-reported rates are typi-
cally from tertiary referral centres with optimised MRI proto-
cols and subspecialist reporters. Even with expert reads, it is
estimated that the use of mpMRI may lead to as many as 25%
of significant cancers being missed, when a radical prostatec-
tomy specimen is used as the reference method [6, 7]. One
reason for inaccurate detection of significant cancer in
mpMRI could be that mpMRI interpretation accuracy highly
depends on the experience of the reader [8–14]. Currently, it is
estimated that 100 mpMRI reports supervised by a systematic
double-reader and validated by histopathology are needed to
gain sufficient reader competence [15], and subsequently at
least 50 mpMRIs per year are required to maintain experience
levels [16]. Whilst PI-RADS version 1 focused mainly on
minimal and optimal MRI protocol standards, the more re-
cently updated PI-RADS version 2 concentrates on
standardisation of reading, highlighting a perceived problem
[17, 18].
In our region, patients with previous negative biopsies or
on active surveillance are often referred from local hospitals to
our tertiary centre for further biopsies. These patients have
usually undergone previous mpMRI at their referring hospital,
which is then second-read by local subspecialist
uroradiologists at the tertiary centre prior to biopsy. It has
previously been shown that second-opinion interpretations
of mpMRI significantly improve sensitivity for extracapsular
extension of prostate cancer, even after adjustment for differ-
ences in imaging techniques [13], with limited retrospective
data also suggesting this may be the case for improving detec-
tion of clinically relevant lesions in false-negative mpMRIs
[19]. Thus, the aim of this study was to investigate whether
prospective second opinion evaluation of prostate mpMRI by
subspecialist uroradiologists at a tertiary centre affects the pre-
dictive values of the report prior to transperineal fusion
biopsy.
Materials and methods
Study population
This single-institution study was part of an evaluation of
transperineal prostate biopsies with the need for informed
consent for data analysis waived by the local ethics commit-
tee. From April 2013 to February 2016, 158 consecutive pa-
tients referred for transperineal prostate biopsies from regional
hospitals and meeting inclusion criteria were included for
analysis. Minimum MRI criteria were based on the
European Society of Urogenital Radiology (ESUR) 2012
guidance (below) [20]. Patients were referred through an
agreed pathway either for active surveillance for repeat sur-
veillance biopsy, or in patients with negative systematic biop-
sy but ongoing suspicion of cancer based on prostate-specific
antigen (PSA), symptoms or prior high risk biopsy, based on
UK guidance. The clinical objective was to identify signifi-
cant cancer necessitating treatment, defined as Gleason score
7-10. Thirty-three patients on active surveillance for Gleason
3+3 disease were included for retrospective analysis; 125 pa-
tients had previous negative systematic transrectal ultrasound
(TRUS)-guided biopsies (Supplementary Fig. 1). Patients on
active monitoring for Gleason score 7 cancer were therefore
excluded from the analysis, as their disease already met our
criteria for clinically significant cancer. The Standards of
Reporting for MRI-targeted Biopsy Studies (START) were
used to describe the study population, the conduct and
reporting of the MRI, and the conduct of the biopsy and the
Standards of Reporting of Diagnostic Accuracy (STARD)
were used to describe and discuss the results [21, 22].
Magnetic resonance imaging
Patients underwent prostate mpMRI at seven different region-
al hospitals on either 1.5-T (87/158) or 3.0-T (71/158) MRI
scanners with surface coil and no endorectal coil. Minimum
sequence requirements for inclusion in the study were axial
T1-weighted images (T1WIs) of the pelvis, high resolution
axial T2-weighted images (T2WIs) of the prostate and
diffusion-weighted imaging (DWI), with a minimum of two
b values, with a high b value of 800-1,000 [20]. Apparent
diffusion coefficient (ADC) maps were calculated for all pa-
tients. Eight percent (12/158) of mpMRIs included dynamic
contrast-enhanced sequences.
Image analysis
All mpMRIs were performed and first-read at seven regional
referral centres by 28 different radiologists. Data on the refer-
ring radiologists’ experience in reporting mpMRIs of the pros-
tate were not available. All mpMRI images were prospective-
ly second-read at our own tertiary centre, with external reports
available. Second reads were performed by one of two sub-
specialist uroradiologists with 6 (over 1,500 cases) and 4 years
(over 1,000 cases) of experience in reading prostate MRI. In
the second-read, T2WI and DWI sequences were evaluated
using a Likert scale of tumour probability, based on the
Prostate Imaging Reporting and Data System (PI-RADS
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version 1) structured scoring criteria developed by the ESUR
[20] and a final score was defined by combining all scores for
T2WI and DWI sequences as recommended in PI-RADS ver-
sion 2 [23]. This second read was performed contemporane-
ously, soon after initial MRI acquisition and before the biopsy
procedure, therefore prospectively affecting the biopsy
targeting. For patients in whom more than one MRI had been
performed, all studies were available to both internal and ex-
ternal readers. The Likert-based scoring system was as fol-
lows: 1 = cancer highly unlikely, 2 = cancer unlikely, 3 =
equivocal for cancer, 4 = cancer likely, 5 = cancer highly
likely. Lesion probability only, rather than quantifiable mea-
sures such as ADC value and measurements were recorded. In
cases where external reports did not explicitly state a
PIRADS/Likert score or location, the reports were reviewed
by two research radiologists in consensus, blinded to the clin-
ical details and retrospectively grouped for suspicion of cancer
as no suspicion (Likert 1-2), equivocal (Likert 3) or suspicion
(Likert 4-5) for cancer.
Biopsy
The BiopseeTM transperineal MRI/TRUS fusion biopsy sys-
tem version 1 or 2 (Medcom, Darmstadt, Germany) was used
for all biopsies. All patients had 18-24 systematic biopsies
taken according to the Ginsburg protocol, using a spring-
loaded biopsy gun with an 18-gauge needle [5, 24]. In patients
with MRI lesions prospectively called by the subspecialist
reader, two biopsy cores were taken from each Likert 3-5
lesion before the systematic biopsies. In the systematic biopsy,
two biopsy cores were sampled from each of 12 sectors,
starting with the anterior sectors. All procedures were under-
taken by one of three urologists with several years’ experience
of transperineal biopsy using the Biopsee MRI/TRUS fusion
biopsy system.
Histopathology
All biopsies were reported by a specialist uropathologist and
were reviewed a second time, by another uropathologist, prior
to discussion at a multidisciplinary team meeting. Biopsies
were reviewed according to the ISUP 2005 recommendations
[25]. The final Gleason score was used as data for this study.
Statistics
The absolute and relative agreements of initial and ter-
tiary centre reads were calculated. Kappa coefficient cal-
culation was used to compare distribution into the differ-
ent probability subgroups. It was also analysed in how
many cases lesions were called in both reads, how many
reports called different lesions and how often there was
no corresponding lesion at all with the other read being
rated as non-suspicious.
Benign histopathology, prostatitis and Gleason score
(GS) 3 + 3 = 6 were considered as negative histopathol-
ogy. GS 7-10 cancer detection rate, all cancer detection
rate, and positive (PPV) and negative (NPV) predictive
values were calculated for each probability group and
both readings, including targeted and systematic biopsy
cores in the area that the index lesion was located in. For
example: if an index lesion was called in the right ante-
rior, the results for the targeted cores and the systematic
cores in the right anterior were used for analysis. If the
index lesion was called in the initial read but not targeted
after the second read, the systematic cores in the respec-
tive area were used for analysis. Fisher’s exact test was
used to test for statistically significant difference of can-
cer proportions.
Results
Initial reports called 47 % (59/126) index lesions in the
transition zone and 53 % (67/126) in the peripheral zone.
More than one lesion was called in 36/126 patients in the
initial report. After second reading, 44 % (41/94) index
lesions were called in the transition zone and 56 % (53/
94) in the peripheral zone. More than one lesion was
called in 19/94 patients in the subspecialist tertiary-
centre report. At transperineal biopsy, 51 % (80/158) of
patients had a GS 6-10 prostate cancer (PCa), 30 % (47/
158) of patients had a GS ≥3 + 4 PCa and 5 % (8/158) a
GS ≥4 + 3 PCa. The clinical characteristics are shown in
Table 1.
Agreement of probability scoring
The strength of agreement between initial reports and tertiary
centre second-reads was poor in all three groups (Table 2).
Overall, 135 index lesions were identified in 158 patients by
either one or both reads, 126 in initial reports and 94 in
Table 1 Clinical characteristics of the patients included in the study
Total
n
IQR
Median age (years) 65 59-69
Median PSA (ng/mL) 7.7 5.8-12.7
Median volume (cc) 59 40-78
Median PSA density (ng/mL/cm3) 0.14 0.09-0.22
Median number of target cores 2 2-4
Median numbers of systematic cores 24 24-24
PSA prostate-specific antigen, IQR interquartile range
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tertiary-centre second reads. In 33 % (45/135) the same lesion
was called in both reads, in 27 % (37/135) different lesions
were called and in 39 % (53/135) there was no corresponding
lesion at all with the other read being rated as non-suspicious.
NPV of negative MRI (Likert 1-2)
Multiparametric MRIs were more often called negative in
tertiary-centre reads than in initial reports (41 % vs 20 %
Likert 1-2; p = 0.0001) (Table 3). The corresponding NPV
for GS ≥3 + 4 cancer was significantly higher for tertiary-
centre second reads (0.89; 57/64) compared to initial reports
(0.72; 23/32) despite the more frequent calling by tertiary-
centre readers; p = 0.044 (Fig. 1). NPVs for higher grade
(GS ≥4 + 3) tumours were also significantly higher at 0.97
(62/64) and 0.84 (27/32), respectively; p = 0.039.
PPV of equivocal mpMRI (Likert 3)
Regarding the outcome for the individual target area, PPVs
were not significantly different between tertiary centre and
initial reads with 0.24 (8/33) and 0.20 (9/46) for any cancer,
respectively; p = 0.782; and 0.12 (4/33) and 0.11 (5/46) for
GS7-10; p = 1.000 (Table 4).
PPV of suspicious mpMRI (Likert 4-5)
Multiparametric MRIs were less often called suspicious in
tertiary-centre reads than in initial reports (39 % vs 51 %
Likert 4-5; p = 0.04) (Table 5). Regarding the outcome for
the individual target area, PPVs for detecting any cancer were
significantly higher for tertiary-centre reads (0.61; 37/61) than
for initial reads (0.28; 22/80); p = 0.0001 (Figs. 2 and 3). For
detection of GS 7-10 cancer in the target area, PPVs were 0.43
(26/61) with subspecialist second reads versus 0.23 (18/80)
for initial reports; p = 0.017. Regarding the final histopathol-
ogy result for the entire prostate biopsy, PPV for GS7-10
cancer was significantly higher for tertiary-centre second
reads (0.56; 34/61) than for to initial reports (0.34; 27/80),
despite the less frequent calling by tertiary-centre readers; p
= 0.011.
Discussion
Our study shows that second-opinion readings of mpMRI by
subspecialised uroradiologists at a tertiary centre significantly
improved diagnostic accuracy. Multiparametric MRIs were
more often called negative in tertiary-centre reads than in ini-
tial reports (41 % vs 20 % Likert 1-2). A negative mpMRI
tertiary-centre second read by subspecialists had a significant-
ly higher NPV for cancer GS 7-10 than for initial regional
reports (0.89 vs 0.72). PPVs of equivocal MRIs for detecting
cancer in the target area were not significantly different for the
initial and tertiary centre readers with 0.11 vs 0.12 (p = 1.00),
although of note, these were called less frequently called by
the latter. Multiparametric MRIs were also less often called
suspicious in tertiary-centre reads than in initial reports with
39 % vs 51 % (p = 0.04). A suspicious mpMRI by tertiary-
centre read had a significantly higher PPV both for detecting
any cancer (0.61 vs 0.28) and for detecting GS 7-10 cancer
(0.43 vs 0.23) in the target area.
Even though negative mpMRIs were reported more fre-
quently by tertiary-centre radiologists, the NPV of 0.89 was
equivalent to that reported in existing literature [2, 3, 5, 26],
with a significantly lower NPV of 0.72 observed for initial
Table 2 Cross-table of probability scoring between initial reports and second reads. There were 46 % (72/158; kappa value = 0.177) agreements in
grouping for suspicion of cancer as no suspicion (Likert 1-2), equivocal (Likert 3) and suspicion (Likert 4-5) for cancer. The strength of agreement into
the broad groups of MRI being either negative (Likert 1-2) or suspicious (Likert 3-5) was fair (106/158; kappa value = 0.258)
Subspecialist second read
Initial read Likert 1-2 n (%) (%) Likert 3 n (%) Likert 4-5 n (%) Total n (%)
Likert 1-2 22 14 % 3 2 % 7 4 % 32 20 %
Likert 3 18 11 % 12 8 % 16 10 % 46 29 %
Likert 4-5 24 15 % 18 11 % 38 24 % 80 51 %
Total 64 41 % 33 21 % 61 39 % 158 100 %
Table 3 Negative predictive value of non-suspicious mpMRI (Likert 1-2) after a transperineal MRI/TRUS-fusion guided targeted and 18–24-core
systematic prostate biopsy according to the Ginsburg protocol
Likert 1-2 Total (n) % of total GS 7-10 (n) NPV 95 % CI p value GS ≥4 + 3 (n) NPV 95 % CI p value
External report 32 20 % 9 0.72 0.56-0.88 0.04 5 0.84 0.71-0.97 0.04
Subspecialist 64 41 % 7 0.89 0.81-0.97 2 0.97 0.93-1.01
GS Gleason score, NPV negative predictive value, CI confidence interval
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Fig. 1 False-negative external report. A 70-year-old patient with 10.4 ng/
ml PSA and previous negative TRUS biopsy. MRI reported as negative
externally. Second report identified a high probability (PIRADS-5) 15-
mm target in the left anterior apex transition zone (arrows), with
homogeneous low T2-signal (a), and restricted diffusion on b-1,400 im-
aging (b) and ADC map (c). Transperineal biopsy found Gleason 3 + 3
disease in 30 % of both target cores
Table 4 The positive predictive values of equivocal multiparametric MRI (Likert 3) using a transperineal MRI/TRUS-fusion guided targeted and 18–
24-core systematic prostate biopsy as the reference test
Likert 3 Total (n) % of total GS 6-10 (n) PPV 95 % CI p value GS 7-10 (n) PPV 95 % CI p value
Target area only
External report 46 29 % 9 0.20 0.08-0.32 0.78 5 0.11 0.02-0.20 1.00
Subspecialist 33 21 % 8 0.24 0.09-0.39 4 0.12 0.01-0.23
Total biopsy
External report 46 29 % 22 0.48 0.33-0.62 1.00 11 0.24 0.12-0.36 0.59
Subspecialist 33 21 % 15 0.45 0.28-0.62 6 0.18 0.05-0.31
GS Gleason score, PPV positive predictive value, CI confidence interval
Table 5 The positive predictive values of suspicious multiparametric MRI (Likert 4-5) using a transperineal MRI/TRUS-fusion guided targeted and
18–24-core systematic prostate biopsy as the reference test
Likert 4-5 Total (n) % of total GS 6-10 (n) PPV 95 % CI p value GS 7-10 (n) PPV 95 % CI p value
Target area only
External report 80 51 % 22 0.28 0.18-0.38 0.01 18 0.23 0.14-0.32 0.02
Subspecialist 61 39 % 37 0.61 0.49-0.73 26 0.43 0.31-0.55
Total biopsy
External report 80 51 % 44 0.55 0.44-0.66 0.08 27 0.34 0.24-0.44 0.01
Subspecialist 61 39 % 43 0.70 0.59-0.82 34 0.56 0.44-0.68
GS Gleason score, PPV positive predictive value, CI confidence interval
Fig. 2 False-positive external report. A 64-year-old patient with 7.1 ng/
ml PSA and previous negative TRUS biopsy. External report described a
high probability target in the left mid peripheral zone. Second read called
a negativeMRI, with linear areas of intermediate T2 signal in the left mid
(a, PIRADS-2) and high signal on b-1,400 imaging (b) thought to be
artefactual due to rectal gas, and without convincing low signal on
ADC maps (c). Subsequent transperineal template biopsy showed all 24
cores to be benign
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reads. This is particularly relevant with the increasing use of
mpMRI prior to initial biopsy, with retrospective data on its
highNPV leading to prospective studies investigatingwhether
a negative MRI can safely allow men to avoid a biopsy and its
associated harms [27]. Our results support the findings of
Gaziev et al. [14], who reported that radiologists undergo a
learning curve with NPVs increasing from 0.67 to 0.89 for
excluding significant cancer with increasing experience.
Additionally, avoiding biopsies in men with a negative MRI
according to tertiary-centre uroradiologists would have led to
missing only 3 % GS ≥4 + 3 PCa, compared with 16 % if an
external radiologist had assigned the MRI as negative.
Urologists need to be aware of this risk when deciding which
patients need to undergo re-biopsy in the context of an ongo-
ing clinical suspicion of cancer, or which can be followed-up
with active surveillance.
Suspicious mpMRIs were called less frequently than in
initial reports, but maintained a higher PPVof 0.61 for detect-
ing any cancer in the target area and 0.56 for detection of GS7-
10 PCa in the total prostate biopsy; results which are similar to
those previously published in centres with subspecialist
uroradiologists [5, 26]. In contrast, the PPV for initial reports
to find any cancer in the target area was 0.28. This implies that
inexperienced radiologists overcall suspicious lesions, while
missing significant cancer elsewhere in the prostate. This is
especially relevant for urologists that want to undertake
targeted biopsies only, without systematic cores. Reporter ex-
perience may reduce overcalling and therefore avoid
overtargeting of lesions called by less experienced readers.
Gaziev et al. [14] found that the detection rate of targeted
biopsy rises from 0.27 up to 0.63 with increasing experience.
In our study, PPV was 0.28 for initial readers, which is at the
lower end of the learning curve reported by Gaziev et al.
Conversely, second reading by subspecialists at a tertiary cen-
tre in our study improved the PPV for finding any cancer in
the target area to 0.61.
A strength of our study is that we used a combination of
targeted and a 24-core systematic transperineal biopsy as the
reference. Next to radical prostatectomy specimens and
transperineal mapping, this is the most valid means of
assessing for clinically significant PCa. Additionally, benign
cases will not undergo prostatectomy and therefore data for
true negatives are not available on a whole-gland, patient-by-
patient basis. Limitations of this study include its retrospective
analysis, with potential for allocation bias in review of exter-
nal reports, and a lack of data on the referring radiologists’
experience in reporting mpMRIs of the prostate. If second
reading was negative, the initially called lesions were not
targeted in the biopsy. To reduce this potential bias against
the initial read, the systematic cores from the equivalent sector
were used for analysis. If this study were to be repeated pro-
spectively, all index lesions called by either read could be
targeted. Subspecialist readers had the advantage of availabil-
ity of the initial report, which may bias decision-making.
However, alliterative error resulting from the influence of
one radiologist on another is more likely to favour concor-
dance [28], and the poor agreement here (44 %) suggests this
did not influence decision-making. In addition, we have no
information on the proportion of referred patients to our centre
and on the referral criteria employed; for instance, cases with
concordant clinical assessment and negative imaging may not
have been referred to our tertiary centre, which could poten-
tially affect the NPV. However, we feel that our results suffi-
ciently emphasise the necessity of adequate experience for
radiologists when reporting prostate mpMRIs.
Our results make the case for subspecialist reading of
mpMRI, particularly in the context of repeat biopsy. At our
centre, the referral for second reading of studies only repre-
sented approximately 10 % of the MRIs performed at the
respective centres. As a high-volume institution, we perform
more MRIs than these centres, but centralised reporting of all
regional studies would still result in a threefold increase in
workload. Aside from increasing the number of central
subspecialised radiologists, another option may be to provide
more training to radiologists at the outside hospitals. A sug-
gested way to achieve this is the adoption of a temporary
intermediate competency certification process based on the
experience of 50–100 cases with a supervised systematic
double-reading by an experienced reader and pathology feed-
back [15, 16].
Conclusions
Second reading of prostate mpMRIs by subspecialised
uroradiologists at a tertiary centre significantly improved the
NPVand PPV. Urologists should be aware that the experience
of the reporter will affect the report when making a decision if
and how to obtain biopsies.
Fig. 3 False-positive external report. A 50-year-old patient with16.6 ng/
ml PSA and previous negative TRUS biopsy. External report described
high probability targets bilaterally and medially at the base peripheral
zone. Second read called a negative MRI, with normal central zone dem-
onstrating low T2 signal (a) and low signal on ADC maps (b, arrows).
Subsequent transperineal template biopsy showed all 24 cores to be
benign
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